- Home
- DVAX vs PHLT Comparison
DVAX vs PHLT Comparison
Compare DVAX & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- PHLT
- Stock Information
- Founded
- DVAX 1996
- PHLT 1976
- Country
- DVAX United States
- PHLT United States
- Employees
- DVAX N/A
- PHLT N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- PHLT Other Consumer Services
- Sector
- DVAX Health Care
- PHLT Consumer Discretionary
- Exchange
- DVAX Nasdaq
- PHLT Nasdaq
- Market Cap
- DVAX 1.3B
- PHLT 601.2M
- IPO Year
- DVAX 2004
- PHLT N/A
- Fundamental
- Price
- DVAX $9.70
- PHLT $7.68
- Analyst Decision
- DVAX Buy
- PHLT Buy
- Analyst Count
- DVAX 4
- PHLT 2
- Target Price
- DVAX $26.50
- PHLT $7.88
- AVG Volume (30 Days)
- DVAX 1.9M
- PHLT 1.2M
- Earning Date
- DVAX 11-06-2025
- PHLT 11-05-2025
- Dividend Yield
- DVAX N/A
- PHLT N/A
- EPS Growth
- DVAX N/A
- PHLT N/A
- EPS
- DVAX N/A
- PHLT N/A
- Revenue
- DVAX $316,268,000.00
- PHLT $137,357,000.00
- Revenue This Year
- DVAX $23.23
- PHLT $12.38
- Revenue Next Year
- DVAX $16.57
- PHLT $10.09
- P/E Ratio
- DVAX N/A
- PHLT N/A
- Revenue Growth
- DVAX 26.66
- PHLT 15.21
- 52 Week Low
- DVAX $9.20
- PHLT $2.17
- 52 Week High
- DVAX $14.63
- PHLT $7.74
- Technical
- Relative Strength Index (RSI)
- DVAX 41.54
- PHLT 53.18
- Support Level
- DVAX $9.20
- PHLT N/A
- Resistance Level
- DVAX $9.94
- PHLT $7.67
- Average True Range (ATR)
- DVAX 0.30
- PHLT 0.03
- MACD
- DVAX -0.05
- PHLT -0.39
- Stochastic Oscillator
- DVAX 40.65
- PHLT 99.74
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.